Quantitative Concept
Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing
Autobahn Therapeutics, Phase II, Mood Disorders, Financing, Pharmaceutical Industry
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
PBM Executives Avoid Tough Questions in House Committee Hearing
PBM executives, House committee hearing, pharmacy benefit managers, CVS Caremark, Express Scripts, Optum Rx
Canaan Partners Raises Additional $100M for Biotech Investments, Adds Pfizer Vet Uwe Schoenbeck
Canaan Partners, Biotech investments, Venture capital, Pfizer, Uwe Schoenbeck, Biopharma, Healthcare, Venture partner
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease
PhRMA Intensifies Pricing Criticism, Targets Shared Ownership of Insurers and PBMs in New Ad
PhRMA, pricing attack, shared ownership, insurers, PBMs, new ad
Biopharma Layoff Tracker 2024: Thousands of Jobs Cut Across Industry Giants
Biopharma Layoffs, 2024, Industry Giants, Job Cuts, Restructuring, Cost Savings
Elevance Health Surpasses Expectations in Q2 with $2.3 Billion Profit
Elevance Health, Q2 earnings, profit, revenue, Carelon, PBM, insurance premiums
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding